COST

971.81

-0.4%↓

PG

154.42

+0.44%↑

KO

69.95

+0.6%↑

PM

166.24

+0.92%↑

PEP

150.33

+1.11%↑

COST

971.81

-0.4%↓

PG

154.42

+0.44%↑

KO

69.95

+0.6%↑

PM

166.24

+0.92%↑

PEP

150.33

+1.11%↑

COST

971.81

-0.4%↓

PG

154.42

+0.44%↑

KO

69.95

+0.6%↑

PM

166.24

+0.92%↑

PEP

150.33

+1.11%↑

COST

971.81

-0.4%↓

PG

154.42

+0.44%↑

KO

69.95

+0.6%↑

PM

166.24

+0.92%↑

PEP

150.33

+1.11%↑

COST

971.81

-0.4%↓

PG

154.42

+0.44%↑

KO

69.95

+0.6%↑

PM

166.24

+0.92%↑

PEP

150.33

+1.11%↑

Search

Hims & Hers Health Inc

Затворен

СекторДефанзивни потребителски стоки

46.12 -2.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

46

Максимум

46.38

Ключови измерители

By Trading Economics

Приходи

-7M

43M

Продажби

-41M

545M

P/E

Средно за сектора

63.266

26.431

Марж на печалбата

7.801

Служители

1,637

EBITDA

-29M

37M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+6.71% upside

Дивиденти

By Dow Jones

Следващи печалби

3.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-2.9B

11B

Предишно отваряне

48.28

Предишно затваряне

46.12

Настроения в новините

By Acuity

50%

50%

60 / 150 Класиране в Consumer defensive

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Hims & Hers Health Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2025 г., 00:05 ч. UTC

Горещи акции

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

29.04.2025 г., 12:54 ч. UTC

Значими двигатели на пазара

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1.04.2025 г., 23:15 ч. UTC

Значими двигатели на пазара

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25.02.2025 г., 15:33 ч. UTC

Значими двигатели на пазара

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18.11.2024 г., 19:07 ч. UTC

Значими двигатели на пазара

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14.10.2024 г., 15:02 ч. UTC

Значими двигатели на пазара

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

5.08.2025 г., 20:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 18:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 17:26 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5.08.2025 г., 15:25 ч. UTC

Печалби

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5.08.2025 г., 11:27 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:55 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:36 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

29.07.2025 г., 16:55 ч. UTC

Печалби

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

24.06.2025 г., 10:26 ч. UTC

Пазарно говорене

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

3.06.2025 г., 15:03 ч. UTC

Придобивния, сливания и поглъщания

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7.05.2025 г., 13:56 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6.05.2025 г., 14:24 ч. UTC

Печалби

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30.04.2025 г., 09:30 ч. UTC

Топ новини

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2.04.2025 г., 16:53 ч. UTC

Топ новини

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19.03.2025 г., 15:54 ч. UTC

Топ новини

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21.02.2025 г., 23:20 ч. UTC

Печалби

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10.02.2025 г., 12:00 ч. UTC

Топ новини

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19.12.2024 г., 17:16 ч. UTC

Топ новини

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19.12.2024 г., 15:14 ч. UTC

Топ новини

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19.12.2024 г., 15:02 ч. UTC

Топ новини

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16.12.2024 г., 13:47 ч. UTC

Топ новини

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16.12.2024 г., 07:00 ч. UTC

Топ новини

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3.10.2024 г., 14:45 ч. UTC

Топ новини

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Hims & Hers Health Inc Прогноза

Ценова цел

By TipRanks

6.71% нагоре

12-месечна прогноза

Среден 49.11 USD  6.71%

Висок 85 USD

Нисък 28 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Hims & Hers Health Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

11 ratings

2

Купи

7

Задържане

2

Продай

Техническа оценка

By Trading Central

36.685 / 52.35Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

60 / 150 Класиране в Дефанзивни потребителски стоки

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.